样式: 排序: IF: - GO 导出 标记为已读
-
The role of the fibroblast in Barrett's esophagus and esophageal adenocarcinoma. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-04-12 Huili Zhu, Ramon U Jin
Barrett's esophagus (BE) is the number one risk factor for developing esophageal adenocarcinoma (EAC), a deadly cancer with limited treatment options that has been increasing in incidence in the US. In this report, we discuss current studies on the role of mesenchyme and cancer-associated fibroblasts (CAFs) in BE and EAC, and we highlight translational prospects of targeting these cells.
-
A practical guide to selecting and using new ulcerative colitis therapies. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-04-12 Tara Nagaraj, John Shinn, Kara De Felice
Several new biologics (mirizikizumab) and small molecules (upadacitinib, ozanimod, etrasimod) are approved for the treatment of moderate-to-severe ulcerative colitis. To date, there are no head-to-head trials to guide positioning and use of these newer agents.
-
A Practical guide to selecting and using new Crohn's disease therapies. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-04-12 Elizabeth A Scoville, Sara N Horst
This review details the three new agents, including two novel mechanisms of action, approved to treat Crohn's disease in recent years. We review efficacy, safety, prescribing information, and available data on positioning these new therapies.
-
Towards personalized management of early esophageal adenocarcinoma. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-04-12 Vincent Bos, Man Wai Chan, Roos E Pouw
This review aims to discuss recent advancements in the endoscopic management of early esophageal adenocarcinoma (T1 EAC).
-
Advances in endoscopic management of colonic diverticular bleeding. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-04-11 Yasutoshi Shiratori, Syed Matthew Kodilinye, Ahmed E Salem
This review is focused on diagnostic and management strategies for colonic diverticular bleeding (CDB). It aims to present the current state of the field, highlighting the available techniques, and emphasizing findings that influence the choice of therapy.
-
Noninvasive assessment of liver fibrosis and portal hypertension. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-03-29 Andres Duarte-Rojo, Keyur Patel, Don C Rockey
The result of ongoing liver injury - and disease, regardless of cause - is fibrosis, and fibrosis appears to be a critically important result of ongoing injury. Further, in a number of different liver diseases, the presence of fibrosis has prognostic value. Therefore, the assessment of fibrosis is of critical clinical importance. Given the importance of fibrosis, there has been a rapid evolution in
-
Update on ischemic hepatitis. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-03-18 Jessica Elizabeth Smith, Don C Rockey
Ischemic hepatitis (IH) refers to diffuse liver injury secondary to hypoperfusion. The condition is usually seen in the critical care setting and is associated with significant mortality. IH typically occurs in the setting of systemic hypotension superimposed on some form of underlying cardiac dysfunction. This review aims to report what is known and what is new about the etiology, pathophysiology
-
Monitoring coeliac disease in 2024, time to change practice? Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-03-14 Suneil A Raju, Mohamed G Shiha, Hugo A Penny
Persistent villous atrophy is associated with morbidity in coeliac disease and most commonly due to ongoing gluten ingestion. Current methods for assessing gluten exposure and persisting villous atrophy include dietary questionnaires and repeat duodenal biopsy, which have limited accuracy or are invasive. This review discusses adjunctive and/or novel tests that could be used to overcome these challenges
-
The role of the microbiome in liver disease. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-02-19 David Schöler, Bernd Schnabl
The intestinal microbiome and the gut-liver axis play a major role in health and disease. The human gut harbors trillions of microbes and a disruption of the gut homeostasis can contribute to liver disease. In this review, the progress in the field within the last 3 years is summarized, focusing on metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD)
-
Advances in the evaluation and treatment of autoimmune hepatitis. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-02-19 M R Pedersen, Marlyn J Mayo
The primary therapy of autoimmune hepatitis (AIH) has been established for over three decades. This review focuses on updates in the evaluation and management of patients with AIH.
-
Diagnosis and management of immune mediated liver injury from checkpoint inhibitors. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-02-16 Alisa Likhitsup, Robert J Fontana
The aim is to summarize the latest data on the incidence, clinical manifestations, and management of immune- mediated liver injury from checkpoint inhibitors (ILICI).
-
COVID-19 vaccine-induced liver injury. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-02-15 Hersh Shroff
The rapid rollout and uptake of novel coronavirus disease 2019 (COVID-19) vaccines has been accompanied by a small yet noticeable accumulation of reports of liver injury occurring after vaccination. This review describes the present evidence surrounding COVID-19 vaccine-induced liver injury (VILI).
-
Idiopathic terminal ileitis: myth or true entity? Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-02-15 Nicoletta Nandi, Foong Way David Tai, Mark McAlindon, Reena Sidhu
Isolated terminal ileitis is an increasing phenomenon identified during colonoscopy. Idiopathic terminal ileitis (IDTI) is a diagnosis of exclusion, representing a significant challenge from a diagnostic and management point of view. This review provides an overview of the most recent and relevant evidence on idiopathic IDTI, focusing on its evolution, the natural history and the management strategies
-
Terlipressin for hepatorenal syndrome. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-02-15 Florence Wong
The definition and diagnostic criteria of hepatorenal syndrome-acute kidney injury (HRS-AKI) has undergone recent changes. A major vasoconstrictor, terlipressin, has recently been approved as pharmacotherapy for HRS-AKI in the United States. The purpose of this review is to familiarize the readers with these new diagnostic criteria of HRS-AKI, and how best to use terlipressin.
-
Biliary stem cells in health and cholangiopathies and cholangiocarcinoma. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-02-08 Vincenzo Cardinale, Savino Paradiso, Domenico Alvaro
This review discusses evidence regarding progenitor populations of the biliary tree in the tissue regeneration and homeostasis, and the pathobiology of cholangiopathies and malignancies.
-
Biologics, small molecule therapies and surgery in small bowel Crohn's disease. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-02-01 Joshua M Steinberg, Reezwana Chowdhury, Sowmya Sharma, Aline Charabaty
The terminal ileum and small bowel (SB) are involved in 30-45% of patients with Crohn's disease, while 20% have both small and large bowel involvement. Ileal Crohn's is associated with higher risk of progression to stricturing and penetrating disease1, hence it's imperative to utilize effective therapies to induce and maintain clinical and endoscopic remission and prevent intestinal complications.
-
Postoperative small bowel Crohn's disease: how to diagnose, manage and treat. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-02-01 Chak Lam Ip, Ray Boyapati, Rahul Kalla
Crohn's disease is a relapsing inflammatory condition and disease recurrence after surgery is common. Significant variation in clinical practice remains despite progress in management of postoperative Crohn's disease. In this review, we summarise current management strategies and guidelines, unmet needs, and research progress in this field.
-
Tight junction proteins and biliary diseases. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-01-22 Grégory Merlen, Thierry Tordjmann
In the pathophysiological context of cholangiopathies and more broadly of hepatopathies, while it is conceptually clear that the maintenance of inter-cholangiocyte and inter-hepatocyte tight junction integrity would be crucial for liver protection, only scarce studies have been devoted to this topic. Indeed, in the liver, alteration of tight junctions, the intercellular adhesion complexes that control
-
Targeting bile salt homeostasis in biliary diseases. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2024-01-11 David C Trampert, Roni F Kunst, Stan F J van de Graaf
Advances in the understanding of bile salt synthesis, transport and signalling show the potential of modulating bile salt homeostasis as a therapeutic strategy in cholestatic liver diseases. Here, recent developments in (pre)clinical research in this field is summarized and discussed.
-
The Rosetta Stone of interactions of mucosa and associated bacteria in the gastrointestinal tract. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-11-21 Serena Berberolli,Mengqi Wu,Francisco M Goycoolea
PURPOSE OF REVIEW Gut microbiota-mucosa-epithelial cells co-exist in an intricate three-way relationship that underpins gut homeostasis, and ultimately influences health and disease conditions. The O-glycans of mucin glycoproteins have been uncovered as a centrepiece of this system, although understanding the phenomena at play at the molecular level has been challenging and subject to significant traction
-
Clostridioides difficile infections; new treatments and future perspectives. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-11-10 Charmaine Normington, Caroline H Chilton, Anthony M Buckley
As a significant cause of global morbidity and mortality, Clostridioides difficile infections (CDIs) are listed by the Centres for Disease Control and prevention as one of the top 5 urgent threats in the USA. CDI occurs from gut microbiome dysbiosis, typically through antibiotic-mediated disruption; however, antibiotics are the treatment of choice, which can result in recurrent infections. Here, we
-
Colon polyps: updates in classification and management. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-11-02 David Dornblaser,Sigird Young,Aasma Shaukat
PURPOSE OF REVIEW Colon polyps are potential precursors to colorectal cancer (CRC), which remains one of the most common causes of cancer-associated death. The proper identification and management of these colorectal polyps is an important quality measure for colonoscopy outcomes. Here, we review colon polyp epidemiology, their natural history, and updates in endoscopic classification and management
-
Diagnosis and management of acute lower gastrointestinal bleeding. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-10-30 Yotam Elimeleh, Ian M Gralnek
We review and summarize the most recent literature, including evidence-based guidelines, on the evaluation and management of acute lower gastrointestinal bleeding (LGIB).
-
Medicinal grade opium tincture for severe diarrhea: effect revisited in observational study. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-10-27 David Dahlgren,Per M Hellström
PURPOSE OF REVIEW Chronic diarrhea is a common disorder that interferes with normal daily activities and results in poor quality of life. Fecal urgency and incontinence often necessitate clinical consultation, but the pathophysiological mechanisms are difficult to differentiate in a clinical setting. Therefore, drugs targeting the opioid receptors, such as diphenoxylate and loperamide, are typically
-
The colitis may be microscopic, but the diarrhea is not: update on the treatment of microscopic colitis and immune checkpoint inhibitor colitis. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-10-23 Ngozi Y Enwerem,Eugene F Yen
PURPOSE OF REVIEW Microscopic colitis is an inflammatory disease of the colon that presents as watery diarrhea with minimal to normal endoscopic changes on colonoscopy. It encompasses two common subtypes, lymphocytic colitis and collagenous colitis, which are both treated similarly.Immune checkpoint inhibitor colitis is among the most common immune-related adverse events. Endoscopic and histological
-
High volume, low volume, or pills, which way should we go? a review of bowel preparation for colonoscopy. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-10-19 Jasmine M Haydel, Anthony A Xu, Nabil M Mansour
Colorectal cancer (CRC) is the second leading cause of adult cancer-related deaths in the United States. Colonoscopy is the gold standard for CRC screening. Adequate bowel preparation prior to colonoscopy is essential for good visualization, which results in higher polyp detection rates and shorter procedural times. Achieving adequate preparation prior to colonoscopy is accomplished approximately 75%
-
Irritable bowel syndrome - less irritable, or better treatments? Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-10-19 Paul Travers, Brian E Lacy, David J Cangemi
Irritable bowel syndrome (IBS) is a chronic, often bothersome disorder of gut-brain interaction (DGBI) characterized by abdominal pain associated with a change in stool frequency and/or caliber. Recent advancements have improved our understanding of the underlying pathophysiology, thus opening new avenues for therapeutic intervention. The purpose of this review is to summarize the current literature
-
Stomach and duodenum: what's current in 2023. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-10-05 Tilak U Shah
-
Updates in endoscopic management of ampullary and duodenal adenomas. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-10-05 Pravallika Chadalavada, Tilak Upendra Shah
Adenomas are the most common benign lesions of the gastrointestinal tract. The current review aims to summarize recent literature regarding risk factors, natural history, diagnostic and staging technique, and management strategies for ampullary and nonampullary duodenal adenomas.
-
Intestinal microbiome in short bowel syndrome: diagnostic and therapeutic opportunities. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-09-19 Fariha Chowdhury, Lee Hill, Nyah Shah, Jelena Popov, Paige Cheveldayoff, Nikhil Pai
The intestinal microbiome plays a strong, complementary role in the development and integrity of the intestinal epithelium. This biology is crucial for intestinal adaptation, particularly after the mucosal insults that lead to short bowel syndrome (SBS). The purpose of this review is to discuss relationships between the intestinal microbiota and the physiology of intestinal adaptation.
-
Small intestinal bacterial overgrowth: current update. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-09-19 Hammad Zafar, Brenda Jimenez, Alison Schneider
This article aims to provide an up-to-date review of small intestinal bacterial overgrowth (SIBO), including etiology and risk factors, clinical manifestations, diagnostic evaluation for suspected SIBO, and therapeutic options.
-
Gastroparesis: time for a paradigm change. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-09-06 Brian E Lacy, Journey L Wise, David J Cangemi
Gastroparesis (GP) is a syndrome defined by symptoms and delayed gastric emptying in the absence of mechanical obstruction. Typical symptoms include nausea, vomiting, abdominal pain, and early satiety. Only one medication is currently FDA-approved for the treatment of GP. This review highlights recent research findings pertaining to GP and provides evidence to support a change in the current GP diagnostic
-
Controversies regarding management of Helicobacter pylori infections. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-09-06 Alyssa Price, David Y Graham, Mimi C Tan
The recognition that Helicobacter pylori should be considered and treated as an infectious disease has yet to fundamentally change diagnostic and treatment practices and has resulted in many controversies.
-
Step on the accelerator: modern treatment of constipation. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-09-04 Daniel Staursky, Dhanush Shimoga, Amol Sharma
This review aims to explore effective management of constipation, examine challenges in making a positive diagnosis, and highlights the significance of a positive patient-provider relationship and emerging treatments.
-
Advances in the treatment of gastric cancer: 2022-2023. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-09-04 David H Ilson
To review 2022-2023 studies in gastric cancer.
-
Therapeutic endoscopy pushing the boundaries: what boundaries? Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-09-01 Anthony N Kalloo
-
Intestinal proteases. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-08-30 Sameer Rao, Madhusudan Grover
Proteases constitute a group of enzymes that hydrolyze peptide bonds. Intestinal proteases are an integral part of gut homeostasis and digestion. This review discusses the broader classification of proteases, regulation of proteolytic activity (PA) in the intestinal tract, and how dysregulation of intestinal proteases contributes to the pathophysiology of conditions such as irritable bowel syndrome
-
Pathophysiology updates: gastroduodenal injury and repair mechanisms. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-08-30 Susan J Hagen
Although the mucosal barrier serves as a primary interface between the environment and host, little is known about the repair of acute, superficial lesions or deeper, persistent lesions that if not healed, can be the site of increased permeability to luminal antigens, inflammation, and/or neoplasia development.
-
Gastric varices. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-08-30 Thomas J Wang, Marvin Ryou
Gastric varices are a rare cause of gastrointestinal bleeding in patients with portal hypertension. There have been significantly advances within endoscopic ultrasound for treatment of gastric varices over the past 5 years in addition to the conventional endoscopic and endovascular therapies. In this review, we will review the latest literature on gastric varices with emphasis on changes to the conventional
-
Population level screening for celiac disease: is now the time? Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-08-25 Brianne Shuler, Edwin Liu, Marisa G Stahl
As incidence and prevalence of celiac disease is increasing, subclinical and asymptomatic presentations are more commonly identified through celiac disease screening. However, the United States Preventive Services Task Force released a statement in 2017 maintaining that there is insufficient evidence to recommend general population screening for celiac disease for asymptomatic individuals. This review
-
Endoscopic therapy for gastroesophageal reflux disease: where are we, where are we going? Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-07-21 Muhammad Haseeb, Christopher C Thompson
Gastroesophageal reflux disease (GERD) is the most common chronic condition with increasing prevalence in the Western world. Despite medical therapy, a considerable proportion of patients continue to experience symptoms, thus fueling the demand for minimally invasive GERD treatment options. This review will assess the currently available endoscopic approaches by analyzing their outcomes data, indication
-
Use of lumen apposing metal stents in patients with altered gastrointestinal anatomy. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-07-20 Yervant Ichkhanian, Manol Jovani
Lumen apposing metal stents (LAMS) have been increasingly used to manage patients with surgically altered anatomy (SAA), who would have otherwise required percutaneous or surgical interventions. Via the creation of de-novo anastomoses, LAMS provides a conduit to access distal parts of the gastrointestinal tract to perform various interventions.
-
A review of deep learning and radiomics approaches for pancreatic cancer diagnosis from medical imaging. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-07-19 Lanhong Yao, Zheyuan Zhang, Elif Keles, Cemal Yazici, Temel Tirkes, Ulas Bagci
Early and accurate diagnosis of pancreatic cancer is crucial for improving patient outcomes, and artificial intelligence (AI) algorithms have the potential to play a vital role in computer-aided diagnosis of pancreatic cancer. In this review, we aim to provide the latest and relevant advances in AI, specifically deep learning (DL) and radiomics approaches, for pancreatic cancer diagnosis using cross-sectional
-
Artificial intelligence in digestive endoscopy: recent advances. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-07-18 Jean-Francois Rey
With the incessant advances in information technology and its implications in all domains of our life, artificial intelligence (AI) started to emerge as a need for better machine performance. How it can help endoscopists and what are the areas of interest in improving both diagnostic and therapeutic endoscopy in each part of the gastrointestinal (GI) tract. What are the recent benefits and clinical
-
Endotherapy in pediatric pancreatitis. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-07-18 Nicholas Norris, David M Troendle
Some children with acute recurrent and chronic pancreatitis stand to benefit from therapeutic endoscopic interventions. The purpose of this review is to summarize specific endoscopic therapies used for these conditions and highlight areas of future research.
-
Endoluminal bariatric and metabolic therapies: state-of-the-art. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-07-14 Nader Bakheet, Dilhana Badurdeen, Adrian Sartoretto, Vivek Kumbhari
The aim of this review is to present the current state of the field, highlight recent developments, and describe the clinical outcomes of these endoluminal bariatric and metabolic procedures.
-
Medical management of hypertriglyceridemia in pancreatitis. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-07-05 Nikola Gligorijevic,Maja Stefanovic-Racic,Erin E Kershaw
PURPOSE OF REVIEW Hypertriglyceridemia-induced acute pancreatitis (HTG-AP) should be considered in all cases of acute pancreatitis and triglyceride levels measured early, so that appropriate early and long-term treatment can be initiated. RECENT FINDINGS In most cases of HTG-AP, conservative management (nothing by mouth, intravenous fluid resuscitation and analgesia) is sufficient to achieve triglyceride
-
Thermal ablative therapies in the gastrointestinal tract. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-06-23 Hendrik Manner
Thermal ablatives therapies have seen an expanding role in gastrointestinal endoscopy during the last years. The aim of this review is to give an overview of the currently available techniques.
-
Endoscopic approaches to small intestinal strictures. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-06-23 Munish Ashat, Rami El-Abiad, Mouen A Khashab
Gastric outlet obstruction (GOO) occurs from benign or malignant causes. Historically, the treatment of benign strictures revolved around endoscopic balloon dilation, whereas, in the case of malignant strictures, the placement of self-expandable metallic stents was the focus. The advent of lumen-apposing metal stent has opened new horizons in addressing shortcomings of enteral stenting and surgical
-
Interpretation of serum pancreatic enzymes in pancreatic and nonpancreatic conditions. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-06-23 Nikhil Bush, Venkata S Akshintala
Serum levels of amylase and lipase can be elevated in nonpancreatic conditions that may or may not be associated with abdominal pain. This leads to a large proportion of patients being falsely labeled as having acute pancreatitis. In this review, we aim to summarize the existing evidence on pancreatic enzyme elevation in various pancreatic and nonpancreatic conditions and its practical implications
-
Endoscopic approaches to the management of hemorrhoids. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-06-22 Syed Matthew Kodilinye, Anthony N Kalloo
To review the literature within the last 5 years on the current status and future perspectives of the endoscopic management of internal hemorrhoids.
-
Role of hyperbaric oxygen therapy in patients with inflammatory bowel disease. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-05-31 Harpreet Kaur, Gursimran Singh Kochhar, Parambir S Dulai
Hypoxia is a known contributor to inflammation in inflammatory bowel diseases (IBD), and a growing interest has emerged in pharmacologically targeting hypoxia response pathways to treat IBD. The most basic form of treatment for hypoxia is delivering higher amounts of oxygen to the intestinal mucosa. In this review, we summarize the evidence in support of hyperbaric oxygen therapy (HBOT), a mechanism
-
In-hospital management of inflammatory bowel disease. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-05-29 Jeffrey A Berinstein, Daniel Aintabi, Peter D R Higgins
The management of hospitalized patients with inflammatory bowel disease (IBD) is complex. Despite considerable therapeutic advancements in outpatient ulcerative colitis and Crohn's disease management, the in-hospital management continues to lag with suboptimal outcomes. The purpose of this review is to provide a brief overview of our approach to managing patients hospitalized with acute severe ulcerative
-
The status of endoscopic therapies for gastroesophageal reflux disease. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-05-29 Jennifer M Kolb, Kenneth J Chang
Gastroesophageal reflux disease (GERD) is exceedingly common and can significantly impact quality of life through heartburn, troublesome regurgitation, or atypical symptoms. The initial approach is conservative lifestyle changes followed by medications with escalation to antireflux surgery as needed. Endoscopic therapy may represent a bridge between pharmacotherapy and surgery and represents an appropriate
-
Identifying individuals at risk of esophageal adenocarcinoma: challenges, existing tools and future steps. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-05-24 Andrew T Kunzmann, Joel H Rubenstein
This review aims to discuss some of the clinical and epidemiological challenges of risk prediction models; summarize the evidence supporting existing models; and highlight the translational requirements.
-
Managing the older adult with inflammatory bowel disease: is age just a number? Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-05-24 Helen Bermudez, Adam S Faye, Bharati Kochar
This review summarizes the most recent literature on older adults with inflammatory bowel diseases (IBD). Additionally, we review geriatric syndromes that may be pertinent to the management of older adults with IBD.
-
Clostridium difficile in inflammatory bowel disease. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-05-16 Tamara Alhobayb, Matthew A Ciorba
The chronic inflammatory bowel diseases (IBD), Crohn's disease, and ulcerative colitis, are associated with an increased risk of symptomatic Clostridium difficile infection (CDI). CDI may also masquerade as an IBD flare and complicate IBD management. This review provides a comprehensive overview of the epidemiology, diagnosis, and treatment of CDI in IBD patients.
-
G-POEM for gastroparesis: past, present and future. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-05-12 Ishaan Vohra, Harishankar Gopakumar, Douglas G Adler
Gastroparesis is a chronic debilitating condition with rising incidence and healthcare burden. As abdominal surgeries, diabetes, viral infections and autoimmune diseases become more prevalent, gastroparesis will continue to upsurge. Conservative treatment options for gastroparesis are limited by their side effects and short-term efficacy. Gastric endoscopic pyloromyotomy (G-POEM) is a novel incisionless
-
Evaluation and management of exocrine pancreatic insufficiency: pearls and pitfalls. Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-05-11 Mitchell L Ramsey, Phil A Hart, Christopher E Forsmark
The diagnosis and management of exocrine pancreatic dysfunction (EPD) can be challenging. EPD classically results from conditions that cause loss of pancreatic acinar cell function and decreased digestive enzyme production. However, several conditions may contribute to signs or symptoms of EPD with otherwise normal pancreatic exocrine function. A thoughtful approach to considering these conditions
-
Machine and deep learning in inflammatory bowel disease Curr. Opin. Gastroenterol. (IF 2.5) Pub Date : 2023-05-10 Fatima Zulqarnain, S. Fisher Rhoads, Sana Syed
Purpose of review The Management of inflammatory bowel disease (IBD) has evolved with the introduction and widespread adoption of biologic agents; however, the advent of artificial intelligence technologies like machine learning and deep learning presents another watershed moment in IBD treatment. Interest in these methods in IBD research has increased over the past 10 years, and they offer a promising